(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1738565

風邪薬とインフルエンザ薬の世界市場規模：タイプ別、用途別、エンドユーザー別、地域範囲別および予測

Global Cold And Flu Drugs Market Size By Type (Antihistamines, Decongestants), By Application (Prescription Medications, Over-the-Counter (OTC) Medications), By End User (Hospitals and Clinics, Retail Pharmacies), By Geographic Scope And Forecast

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.58円
風邪薬とインフルエンザ薬の世界市場規模：タイプ別、用途別、エンドユーザー別、地域範囲別および予測
出版日: 2025年05月12日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

風邪薬とインフルエンザ薬の市場規模と予測

風邪薬とインフルエンザ薬の市場規模は、2024年に168億5,000万米ドルと評価され、2026～2032年にかけてCAGR 7.20%で成長し、2032年には293億9,000万米ドルに達すると予測されます。

  • 風邪薬やインフルエンザ薬は、主に風邪やインフルエンザなどのウイルス性疾患の症状を治療する医薬品です。これらの医薬品には、しばしば市販薬（OTC）の鬱血除去剤、抗ヒスタミン剤、咳止め、アセトアミノフェンやイブプロフェンなどの鎮痛剤が含まれます。状況によっては、重度のインフルエンザ症状を治療するために、配合された抗ウイルス薬が使用されます。これらの治療は感染症を治すものではありませんが、発熱、咳、喉の痛み、鼻づまりなどの症状を緩和し、患者に安心感を与え、病気の間の生活の質を高めます。
  • ウイルス性呼吸器疾患の有病率の上昇と世界人口の増加に伴い、風邪薬とインフルエンザ薬の開発は順調に進むと予想されます。複数の病気を治療する併用療法など、薬の配合の進歩により、患者の利便性と効果が向上すると予測されます。
  • 新規抗ウイルス薬や、市場のインフルエンザ株と闘うための予防接種の開発は、市場の成長を促進します。季節性インフルエンザの予防と健康管理に関する知識の増加、特に大流行時には、市販薬と処方箋による風邪インフルエンザ薬の需要が高水準で推移すると予想されます。遠隔医療とインターネット薬局の出現により、これらの薬剤の世界の入手可能性と消費量が増加します。

風邪薬とインフルエンザ薬の世界市場力学

世界の風邪薬とインフルエンザ薬市場を形成している主要市場力学は以下の通りです。

主要市場促進要因

  • インフルエンザと風邪の罹患率の増加：インフルエンザと風邪の罹患率の増加：世界的にインフルエンザと風邪の罹患率が高いことが、風邪薬とインフルエンザ薬の需要を牽引しています。世界保健機関（WHO）によると、毎年のインフルエンザ流行により、世界中で約300万～500万人の重症患者が発生しています。米国だけでも、疾病対策予防センター（CDC）は、2010～2020年の間に、インフルエンザが原因で年間900万人から4,100万人が罹患したと推定しています。
  • 高齢化人口の増加：高齢者は免疫力が低下しているため、風邪やインフルエンザに感染しやすくなっています。国連経済社会局によると、世界の65歳以上の人口は2050年までに15億人に達し、2020年の7億2,700万人からほぼ倍増すると予想されています。この人口動態の変化により、風邪薬やインフルエンザ薬の需要が増加する可能性が高いです。
  • ヘルスケア支出の増加：特に新興諸国におけるヘルスケア支出の増加が、風邪薬とインフルエンザ薬市場の成長を促進しています。世界銀行のデータによると、GDPに占める世界の医療費の割合は2000年の8.5%から2018年には9.8%に上昇しています。米国では、メディケア・メディケイドサービスセンター（CMS）の報告によると、国民医療費は9.7％成長し、2020年には4.1兆米ドルに達し、GDPの19.7％を占めます。

主要課題

  • 抗ウイルス薬に対する耐性の増加：インフルエンザウイルスの抗ウイルス剤耐性株の出現は、風邪薬とインフルエンザ薬市場に大きな課題をもたらしています。ウイルスが変異すると、オセルタミビル（タミフル）などの既存の抗ウイルス治療に反応しなくなる可能性があります。この耐性により、これらの薬剤の有効性が低下し、病気の長期化や感染率の上昇につながります。製薬会社は、新しい抗ウイルス剤を発見するための研究開発（R&D）に継続的に投資しなければならないが、これには時間とコストがかかります。ウイルスの変異に対応した最新の治療が必要となるため、ヘルスケアのリソースが逼迫し、治療の遅れにつながる可能性があります。
  • 医薬品承認のための規制上のハードル：新しい風邪薬やインフルエンザ薬の承認を得るには、FDAやEMAといった機関による厳しい規制要件のため、長く複雑なプロセスが必要となります。これらの規制は、医薬品の安全性と有効性を確保することを目的としているが、革新的な治療法の導入を遅らせる可能性があります。臨床検査では、薬が症状を緩和するだけでなく、副作用が最小限であることも証明しなければならないです。このような規制状況に対応することは、市場投入までのコストと時間を増加させ、ウイルス株の出現や患者のニーズの変化に迅速に対応する企業の能力を制限する可能性があります。
  • 副作用と安全性への懸念：多くの風邪薬やインフルエンザ薬、特にOTC薬は、眠気、めまい、アレルギー反応などの副作用を伴います。充血除去剤や抗ヒスタミン剤など、成分によっては、高血圧や心臓病などの持病を持つ患者に合併症を引き起こす可能性があります。こうした安全性への懸念から、消費者は特定の製品を避けたり、代替治療を求めたりするようになり、市場の需要に影響を及ぼす可能性があります。

主要動向

  • 呼吸器感染症の有病率の上昇：風邪やインフルエンザなどの呼吸器感染症の罹患率の増加は、風邪薬とインフルエンザ薬市場の主要促進要因のひとつです。気候の変化、都市化の進展、高齢化により、ウイルス感染症にかかりやすくなっています。世界の汚染レベルの上昇は呼吸器の健康を弱め、個人を感染症にかかりやすくします。特に季節性インフルエンザの流行時やCOVID-19のようなパンデミック時には、消費者は生産性を維持するために症状の即時緩和を求めるため、この継続的な動向は市販薬や抗ウイルス薬の需要を増大させています。
  • 市販薬（OTC）への嗜好の高まり：セルフメディケーションへのシフトが進んでおり、OTCの風邪薬やインフルエンザ薬を選ぶ消費者が増えています。この動向の背景には、入手のしやすさ、手ごろな価格、ヘルスケア専門家を訪ねることなく症状に対処したいという願望などがあります。多くのOTC医薬品は、複数の症状に1つの製品で対応するコンビネーション治療を行っています。処方箋なしで薬局やオンラインプラットフォームでこれらの医薬品を購入できる利便性が、需要の増加に大きく寄与しています。
  • 併用療法の需要：鼻づまり、咳、頭痛など複数の症状に1回の服用で対応する併用療法を求める消費者が増えています。この動向を後押ししているのは利便性であり、患者は異なる症状に対して複数の薬を服用するよりも、オールインワンのソリューションを好みます。製薬会社は、一般的な風邪やインフルエンザの症状を緩和する多症状治療の開発でこれに応えてきました。複数の症状を同時に管理できるこれらの治療法は、多忙なライフスタイルを送る個人にとって魅力的であり、風邪薬とインフルエンザ薬市場の重要な促進要因となっています。

目次

第1章 世界の風邪薬とインフルエンザ薬市場の導入

  • 市場概要
  • 調査範囲
  • 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • バリデーション
  • 一次資料
  • データソース一覧

第4章 世界の風邪薬とインフルエンザ薬市場展望

  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • ポーターのファイブフォースモデル
  • バリューチェーン分析

第5章 風邪薬とインフルエンザ薬の世界市場：タイプ別

  • 概要
  • 抗ヒスタミン薬
  • うっ血除去薬

第6章 風邪薬とインフルエンザ薬の世界市場：用途別

  • 概要
  • 処方薬
  • 市販薬

第7章 風邪薬とインフルエンザ薬市場：エンドユーザー別

  • 病院クリニック
  • 小売薬局

第8章 風邪薬とインフルエンザ薬の世界市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
    • その他のラテンアメリカ
  • 中東・アフリカ
    • アラブ首長国連邦
    • サウジアラビア
    • 南アフリカ
    • その他の中東・アフリカ

第9章 世界の風邪薬とインフルエンザ薬市場の競合情勢

  • 概要
  • 各社の市場ランキング
  • 主要開発戦略

第10章 企業プロファイル

  • Johnson & Johnson
  • GlaxoSmithKline, Pfizer
  • Novartis
  • Sanofi
  • AstraZeneca
  • Bayer
  • Reckitt Benckiser
  • Procter & Gamble
  • Mylan
  • Pfizer

第11章 付録

  • 関連調査
目次
Product Code: 61559

Cold And Flu Drugs Market Size And Forecast

Cold And Flu Drugs Market size was valued at USD 16.85 Billion in 2024 and is projected to reach USD 29.39 Billion by 2032, growing at a CAGR of 7.20% from 2026 to 2032.

  • Cold and flu drugs are medical products that treat the symptoms of viral diseases, primarily the common cold and influenza. These medications often include over-the-counter (OTC) decongestants, antihistamines, cough suppressants, and pain relievers such as acetaminophen or ibuprofen. In some situations, prescription antiviral drugs are utilized to treat severe flu symptoms. While these treatments do not cure infections, they do alleviate symptoms such as fever, cough, sore throat, and nasal congestion, giving patients relief and enhancing their quality of life during the illness.
  • The market for cold and flu medications is expected to develop steadily as the prevalence of viral respiratory diseases rises and the worldwide population grows. Advances in medicine formulations, such as combination therapies that treat several ailments, are predicted to improve patient convenience and effectiveness.
  • The development of novel antiviral medicines and vaccinations to combat developing flu strains will aid market growth. With increased knowledge of seasonal flu prevention and health management, particularly during the pandemic, demand for both over-the-counter and prescription cold and flu treatments is expected to stay high. The advent of telemedicine and internet pharmacies will increase the global availability and consumption of these drugs.

Global Cold And Flu Drugs Market Dynamics

The key market dynamics that are shaping the global cold and flu drugs market include:

Key Market Drivers:

  • Increasing Incidence of Influenza and Common Cold: The high prevalence of influenza and common cold cases globally drives the demand for cold and flu medications. According to the World Health Organization (WHO), annual influenza epidemics result in about 3 to 5 million cases of severe illness worldwide. In the United States alone, the Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in 9 million to 41 million illnesses annually between 2010 and 2020.
  • Growing Aging Population: The elderly population is more susceptible to cold and flu infections due to weakened immune systems. The United Nations Department of Economic and Social Affairs reports that the global population aged 65 and above is expected to reach 1.5 billion by 2050, nearly doubling from 727 million in 2020. This demographic shift is likely to increase the demand for cold and flu medications.
  • Rising Healthcare Expenditure: Increased healthcare spending, particularly in developing countries, is driving the growth of the cold and flu drugs market. The World Bank data shows that global health expenditure as a percentage of GDP has risen from 8.5% in 2000 to 9.8% in 2018. In the United States, the Centers for Medicare & Medicaid Services (CMS) reported that national health spending grew 9.7% to reach $4.1 trillion in 2020, accounting for 19.7% of GDP.

Key Challenges:

  • Growing Resistance to Antiviral Medications: The emergence of antiviral-resistant strains of flu viruses presents a significant challenge in the cold and flu drugs market. As viruses mutate, they can become less responsive to existing antiviral treatments, such as oseltamivir (Tamiflu). This resistance diminishes the effectiveness of these drugs, leading to prolonged illness and increased transmission rates. Pharmaceutical companies must continuously invest in research and development (R&D) to discover new antiviral agents, which can be time-consuming and costly. The need for updated treatments in response to viral mutations can strain healthcare resources and lead to treatment delays.
  • Regulatory Hurdles for Drug Approval: Gaining approval for new cold and flu drugs can be a lengthy and complex process due to stringent regulatory requirements from bodies like the FDA and EMA. These regulations aim to ensure the safety and efficacy of medications but can delay the introduction of innovative treatments. Clinical trials must demonstrate not only that the drugs alleviate symptoms but also that they have minimal side effects. Navigating this regulatory landscape can increase the cost and time to market, limiting the ability of companies to swiftly respond to emerging viral strains or changing patient needs.
  • Side Effects and Safety Concerns: Many cold and flu medications, especially OTC options, are associated with side effects like drowsiness, dizziness, or allergic reactions. Certain ingredients, such as decongestants or antihistamines, can cause complications in patients with pre-existing conditions like hypertension or heart disease. These safety concerns may lead consumers to avoid certain products or seek alternative treatments, thereby affecting market demand.

Key Trends:

  • Rising Prevalence of Respiratory Infections: The increasing incidence of respiratory infections, such as colds and the flu, is one of the primary drivers of the cold and flu drugs market. Changes in climate, growing urbanization, and an aging population contribute to higher susceptibility to viral infections. The global rise in pollution levels weakens respiratory health, making individuals more prone to infections. This ongoing trend increases the demand for over-the-counter medications and antiviral drugs, as consumers seek immediate relief from symptoms to maintain productivity, particularly during seasonal flu outbreaks and pandemics like COVID-19.
  • Growing Preference for Over-the-counter (OTC) Drugs: There is a growing shift toward self-medication, with consumers increasingly opting for OTC cold and flu drugs. This trend is driven by factors like easy accessibility, affordability, and the desire to manage symptoms without visiting healthcare professionals. Many OTC medications offer combination treatments, addressing multiple symptoms in a single product. The convenience of purchasing these drugs at pharmacies or online platforms without a prescription has contributed significantly to their rising demand
  • Demand for Combination Therapies: Consumers are increasingly seeking combination therapies that address multiple symptoms such as congestion, cough, and headaches in a single dose. This trend is driven by the convenience factor, as patients prefer all-in-one solutions rather than taking multiple drugs for different symptoms. Pharmaceutical companies have responded by developing multi-symptom medications that offer relief for common cold and flu symptoms. The efficiency of these treatments in managing several symptoms simultaneously appeals to individuals with busy lifestyles, making them a significant driver of the cold and flu drugs market.

Global Cold And Flu Drugs Market Regional Analysis

Here is a more detailed regional analysis of the global cold and flu drugs market:

North America:

  • North America's dominance in the cold and flu drugs market, including the high incidence of respiratory illnesses and an advanced healthcare infrastructure. The United States alone experiences millions of flu cases annually, with the CDC reporting an average of 9 million to 45 million influenza cases each year. This, combined with widespread access to healthcare and over-the-counter (OTC) medications, creates a robust demand for cold and flu treatments.
  • The aging population in North America, which is more vulnerable to respiratory infections, fuels the need for effective and accessible cold and flu drugs. Increased awareness around self-medication for minor ailments and the availability of OTC products further support the market's growth.
  • The cold and flu drugs market is projected to grow at a compound annual growth rate (CAGR) of 5.8% from 2023 to 2028. Heightened awareness due to the COVID-19 pandemic has led to a surge in demand for respiratory illness treatments, further boosting the market. Significant investments in research and development, like the NIH's allocation of $484 million for influenza research in 2023, underline the region's commitment to advancing respiratory treatments.

Asia Pacific:

  • The cold and flu drugs market in the Asia Pacific region is experiencing rapid growth. The region's large and expanding population, which accounts for about 60% of the global population, plays a central role in the market's expansion. Rising urbanization and increased pollution levels contribute to a higher incidence of respiratory illnesses, fueling the demand for cold and flu medications. The growing middle class and rising disposable incomes across the region enable more people to invest in healthcare products, including over-the-counter (OTC) medications. Southeast Asia, in particular, has seen annual healthcare expenditure growth rates between 6-12%, highlighting a significant increase in healthcare access and spending.
  • Another critical driver is the region's aging population, particularly in East Asia and the Pacific, where the percentage of people aged 60 and above is expected to rise from 13.8% in 2020 to 27.6% by 2050. Older adults are more vulnerable to respiratory infections, increasing the demand for cold and flu drugs. The region's expanding healthcare infrastructure, government initiatives to improve healthcare access, and the rise of e-commerce platforms have made cold and flu medications more accessible.

Global Cold And Flu Drugs Market: Segmentation Analysis

The Global Cold And Flu Drugs Market is Segmented on the basis of Type, Application, End User, And Geography.

Cold And Flu Drugs Market, By Type

  • Antihistamines
  • Decongestants

Based on Type, the market is fragmented into Antihistamines and decongestants. Antihistamines dominate due to their widespread use in managing symptoms such as sneezing, runny nose, and watery eyes, which are common in colds and flu. They are a key component in many over-the-counter cold remedies and are favored for their ability to provide quick relief from allergy-like symptoms associated with viral infections. Decongestants are a rapidly growing segment, driven by the rising demand for medications that relieve nasal congestion and sinus pressure, particularly during flu seasons. Decongestants are often sought after for their effectiveness in reducing inflammation and easing breathing, making them essential in cold and flu treatment.

Cold And Flu Drugs Market, By Application

  • Prescription Medications
  • Over-the-Counter (OTC) Medications

Based on Application, the market is divided into Prescription Medications and over-the-counter (OTC) Medications. Over-the-counter (OTC) Medications dominate due to their ease of accessibility and wide availability without the need for a doctor's prescription. Consumers prefer OTC medications for immediate relief from common cold and flu symptoms, making them the go-to choice during seasonal outbreaks. This segment is driven by consumer awareness and the convenience of purchasing from pharmacies, supermarkets, and online platforms. Prescription Medications are rapidly growing, particularly for severe or persistent cases that require more specialized treatments.

Cold And Flu Drugs Market, By End User

  • Hospitals and Clinics
  • Retail Pharmacies

Based on End User, the market is segmented into Hospitals and Clinics, and Retail Pharmacies. Retail Pharmacies dominate due to their accessibility and convenience for consumers seeking over-the-counter medications. Retail pharmacies are widely available, making them the first point of contact for people looking for quick relief from cold and flu symptoms. The rise of online pharmacies has further fueled this segment's growth. Hospitals and Clinics represent a rapidly growing segment, particularly for more severe cases requiring prescription medications or treatment for complications. Increased healthcare visits during flu seasons and the growing preference for professional consultations in complex cases are driving the demand in this segment.

Cold And Flu Drugs Market, By Geography

  • North America
  • Asia Pacific
  • Europe
  • Rest of the world
  • On the basis of geographical analysis, the Global Cold And Flu Drugs Market is classified into North America, Asia Pacific, Europe, and Rest of the world. North America stands out as a dominant region due to its advanced healthcare system, high awareness of cold and flu treatments, and strong consumer demand for over-the-counter drugs. Asia Pacific is experiencing rapid growth, driven by increasing healthcare access, rising disposable incomes, and a growing population.

Key Players

The "Global Cold And Flu Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Johnson & Johnson, GlaxoSmithKline, Pfizer, Novartis, Sanofi, AstraZeneca, Bayer, Reckitt Benckiser, Procter & Gamble, and Mylan. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Cold And Flu Drugs Market Recent Developments
  • In September 2023, BMS disclosed that as part of a strategic license and partnership to create and market obexelimab, a brand-new, bi-functional antibody for autoimmune disorders, it will pay Zenas BioPharma $50 million upfront.
  • In May 2022, Nature's Way Products, LLC, announced a significant expansion of its Green Bay, Wisconsin, Gummy factory. Incorporating production, packaging, and warehouse space, the development will increase the present 80,000 square feet by 116,000 square feet. Early summer was the planned start date, and the project should be finished by the end of the third quarter of 2023.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL COLD AND FLU DRUGS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL COLD AND FLU DRUGS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porter's Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL COLD AND FLU DRUGS MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Antihistamines
  • 5.3 Decongestants

6 GLOBAL COLD AND FLU DRUGS MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Prescription Medications
  • 6.3 Over-the-Counter (OTC) Medications

7 COLD AND FLU DRUGS MARKET, BY END USER

  • 7.1 Hospitals and Clinics
  • 7.2 Retail Pharmacies

8 GLOBAL COLD AND FLU DRUGS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 The U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 The U.K.
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 7.5.3 Rest of LATAM
  • 8.6 Middle East and Africa
    • 8.6.1 UAE
    • 8.6.2 Saudi Arabia
    • 8.6.3 South Africa
    • 8.6.4 Rest of the Middle East and Africa

9 GLOBAL COLD AND FLU DRUGS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Johnson & Johnson
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 GlaxoSmithKline, Pfizer
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Novartis
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Sanofi
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 AstraZeneca
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Bayer
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Development
  • 10.7 Reckitt Benckiser
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Procter & Gamble
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Development
  • 10.9 Mylan
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Development
  • 10.10 Pfizer
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Development

11 Appendix

  • 11.1 Related Research